MDxHealth SA (NASDAQ:MDXH) Given Average Rating of "Moderate Buy" by Analysts

NodeGuardian · 2026-03-02T18:26:35+00:00

MDxHealth SA (NASDAQ:MDXH) has a "Moderate Buy" rating from analysts, with a one-year price target of $7.75. The company specializes in urological cancers and has a current market cap of $171.7M.

NodeGuardian

2026-03-02 18:26:35

Abstract generation in progress

MDxHealth SA (NASDAQ:MDXH) has received an average “Moderate Buy” rating from analysts, with an average one-year price target of $7.75. This consensus stems from five research firms, including one sell rating and four buy ratings. The molecular diagnostics company, focusing on urological cancers, opened at $3.63 with a market cap of $171.7M and a negative P/E of -5.67.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes